KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Intangibles (2016 - 2025)

Historic Intangibles for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $623.5 million.

  • Supernus Pharmaceuticals' Intangibles rose 1542.61% to $623.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $623.5 million, marking a year-over-year increase of 1542.61%. This contributed to the annual value of $521.9 million for FY2024, which is 1299.86% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Intangibles stood at $623.5 million, which was up 1542.61% from $481.3 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Intangibles peaked at $784.7 million during Q4 2021, and registered a low of $346.6 million during Q3 2021.
  • For the 5-year period, Supernus Pharmaceuticals' Intangibles averaged around $587.9 million, with its median value being $599.9 million (2023).
  • In the last 5 years, Supernus Pharmaceuticals' Intangibles soared by 142142.16% in 2021 and then plummeted by 1575.16% in 2024.
  • Supernus Pharmaceuticals' Intangibles (Quarter) stood at $784.7 million in 2021, then decreased by 10.48% to $702.5 million in 2022, then dropped by 14.6% to $599.9 million in 2023, then fell by 13.0% to $521.9 million in 2024, then increased by 19.46% to $623.5 million in 2025.
  • Its last three reported values are $623.5 million in Q3 2025, $481.3 million for Q2 2025, and $502.1 million during Q1 2025.